Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04643639 | Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis | PHASE3 | COMPLETED | 24 | — | — | Sep 16, 2020 | Oct 19, 2022 | Dec 22, 2022 | 1 | Netherlands |
Blood samples will be obtained at predefined time points before, during and after endotoxin administration to assess plasma levels (in pg/mL) of circulating inflammatory mediatiors. To assess between group differences, the area under the curve (AUC) of the time concentration curve (expressed in arbitrary units) of each inflammatory mediator will be calculated.
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | - |
| Control | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| CytoSorb hemoperfusion | DEVICE | Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia. |
Inclusion Criteria: * Provide written informed consent * Male * Age ≥ 18 and ≤ 35 years * Healthy (as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) and routine clinical laboratory parameters) Exclusion Criteria: * Use of any medication * Smoking...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| ImmunityBio Inc | IBRX | 1 | PHASE2 | Nogapendekin alfa inbakicept |
| Bluejay Diagnostics, Inc. | BJDX | 2 | — | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | — | Undisclosed |
| Danaher Corporation | DHR | 3 | — | Undisclosed |
| Spectral AI, Inc. Class A | MDAI | 1 | NA | Undisclosed |